Second-Line Solutions in Metastatic TNBC: ADC Selection, Sequencing, and Safety
- Author
- ReachMD
- Published
- Tue 25 Mar 2025
- Episode Link
- http://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/
CME credits: 0.25
Valid until: 25-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/
Valid until: 25-03-2026
Claim your CME credit at https://reachmd.com/programs/cme/second-line-solutions-in-metastatic-tnbc-adc-selection-sequencing-and-safety/32680/
When choosing an antibody-drug conjugate (ADC) for the second-line treatment of triple-negative breast cancer (TNBC), efficacy, sequencing, and management of toxicities are key. Do you know how best to choose a therapy for your patients? Our experts have the answers and strategies you need!
=